АНТИМЕТАСТАТИЧНА ДІЯ ЛЕКТИНУ B. SUBTILIS IMB B-7724 НА МОДЕЛІ КАРЦИНОМИ ЛЕГЕНІ ЛЬЮЇС

• Date: 2023
• Main Authors: Fedosova, N.I., Symchych, T.V., Cheremshenko, N.L., Chumak, A.V., Koval, E.V., Karaman, O.M., Voyeykova, I.M.
• Format: Article
• Language: English
• Published: PH Akademperiodyka 2023
• Subjects: карцинома легені Льюїс; лектин В. subtilis ІМВ В-7724; протипухлинний ефект; антиметастатичний ефект.
• Online Access: https://exp-oncology.com.ua/index.php/Exp/article/view/2022-2-14
• Journal Title: Experimental Oncology

Aim: To study the antitumor and antimetastatic effects of B. subtilis IMV B-7724 lectin used in neoadjuvant and adjuvant settings in vivo. Materials and Methods: Studies were performed on C57Bl/6J mice; Lewis lung carcinoma (LLC) was used as an experimental tumor. В. subtilis ІМV В-7724 lectin was administered to tumor-bearing mice or to mice which underwent surgical resection of the primary tumor. The lectin was injected subcutaneously, 10 times, at a single dose of 5 or 1 mg/kg of body weight. The standard indicators of tumor growth and metastasis were evaluated. Results: Independently of the application settings, the lectin at a dose of 1 mg/kg of b.w. caused more pronounced effect than at a dose of 5 mg/kg of b.w. The administration of B. subtilis IMV B-7724 lectin to the mice with LLC in neoadjuvant setting did not cause notable antitumor effect but led to a significant decrease in the number and volume of lung metastases. The lectin administration in adjuvant setting significantly inhibited metastasis: the metastasis inhibition index reached 63.0% and 100% in the mice treated with the lectin at a dose of 5 mg/kg and 1 mg/kg respectively. The mean survival time of the treated animals significantly increased. Conclusion: A pronounced antimetastatic effect of B. subtilis IMV B-7724 lectin administered in an adjuvant setting was demonstrated.